Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $204

Benzinga · 1d ago
Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $148 to $204.